A role of CD16 positive monocytes in epidermal damage of severe drug rash

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K08806
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53050:Dermatology-related
• Research Institution: National Hospital Organization Shikoku Cancer Center
• Principal Investigator: Tohyama Mikiko 独立行政法人国立病院機構四国がんセンター(臨床研究センター), その他部局等, 部長 (60263935)
• Co-Investigator(Kenkyū-buntansha): 難波 千佳 愛媛大学, 医学部附属病院, 医員 (50736139)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 重症皮膚障害 / 免疫チェックポイント阻害薬 / 単球 / TNF-α

Outline of Final Research Achievements

Stevens-Johnson syndrome (SJS)/ toxic epidermal necrolysis (TEN)-like epidermal disorders that occur during treatment with immune checkpoints were compared with those of SJS/TEN and erythema multiforme (EM) induced as drug adverse reactions by immunohistochemical analysis. Characteristic of CD16-positive monocytes infiltrating SJS/TEN-like erythema that occur during administration of immune checkpoint inhibitors were considered to resemble that of CD16-positive monocytes infiltrating in EM. In the SJS / TEN-like erythema during treatment with immune checkpoint inhibitor, the epidermis showed a different pattern of molecular expression from SJS/TEN. These findings suggest that epidermal damage caused by the use of immune checkpoint inhibitors may occur by a different type of mechanism from that of SJS/TEN.

Free Research Field

皮膚科学

Academic Significance and Societal Importance of the Research Achievements

本研究は、Stevens-Johnson症候群(SJS)・中毒性表皮壊死症(TEN)と、免疫チェックポイント阻害薬使用時に出現する表皮障害を伴う紅斑では、表皮障害の発生メカニズムが異なることを明らかにした。これらの成果は、SJS/TENの病態形成において重要度の高い要因を検討するうえで、また、免疫チェックポイント阻害薬投与中の表皮障害を伴う皮膚障害の治療法を検討するうえで、学術的、社会的意義がある。